Drug Profile
GRT 6012
Alternative Names: GRT-6012Latest Information Update: 18 May 2016
Price :
$50
*
At a glance
- Originator Grunenthal
- Class Analgesics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Pain
Highest Development Phases
- No development reported Pain
Most Recent Events
- 18 May 2016 No recent reports on development identified - Phase-I for Pain in Germany (unspecified route)